Sanjay Asrani1, Alan L Robin2, Janet B Serle3, Richard A Lewis4, Dale W Usner5, Casey C Kopczynski6, Theresa Heah6. 1. Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: sanjay.asrani@duke.edu. 2. Wilmer Institute and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA; Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA. 3. Icahn School of Medicine at Mount Sinai School, New York, New York, USA. 4. Aerie Pharmaceuticals, Inc., Irvine, California, Bedminster, New Jersey, and Durham, North Carolina, USA; Sacramento Eye Consultants, Sacramento, California, USA. 5. Statistics & Data Corporation, Tempe, Arizona, USA. 6. Aerie Pharmaceuticals, Inc., Irvine, California, Bedminster, New Jersey, and Durham, North Carolina, USA.
Abstract
PURPOSE: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination (FDC) of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost. DESIGN: Three-month primary endpoint analysis of a randomized, double-masked, phase 3 clinical trial. METHODS:Adults with open-angle glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0.02%, or latanoprost 0.005% for up to 12 months. The primary efficacy endpoint was mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3. RESULTS: Mean treated IOP ranged from 14.8-16.2 mm Hg for netarsudil/latanoprost FDC, 17.2-19.0 mm Hg for netarsudil, and 16.7-17.8 mm Hg for latanoprost. Netarsudil/latanoprost FDC met the criteria for superiority to each active component at all 9 time points (all P < .0001), lowering IOP by an additional 1.8-3.0 mm Hg vs netarsudil and an additional 1.3-2.5 mm Hg vs latanoprost. At month 3, the proportion of patients achieving mean diurnal IOP ≤15 mm Hg was 43.5% for netarsudil/latanoprost FDC, 22.7% for netarsudil, and 24.7% for latanoprost. No treatment-related serious adverse events were reported; treatment-related systemic adverse events were minimal. The most frequent ocular adverse event was conjunctival hyperemia (netarsudil/latanoprost FDC, 53.4%; netarsudil, 41.0%; latanoprost, 14.0%), which led to treatment discontinuation in 7.1% (netarsudil/latanoprost FDC), 4.9% (netarsudil), and 0% (latanoprost) of patients. CONCLUSIONS: Once-daily netarsudil/latanoprost FDC demonstrated IOP reductions that were statistically and clinically superior to netarsudil and latanoprost across all 9 time points through month 3, with acceptable ocular safety.
RCT Entities:
PURPOSE: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination (FDC) of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost. DESIGN: Three-month primary endpoint analysis of a randomized, double-masked, phase 3 clinical trial. METHODS: Adults with open-angle glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0.02%, or latanoprost 0.005% for up to 12 months. The primary efficacy endpoint was mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3. RESULTS: Mean treated IOP ranged from 14.8-16.2 mm Hg for netarsudil/latanoprost FDC, 17.2-19.0 mm Hg for netarsudil, and 16.7-17.8 mm Hg for latanoprost. Netarsudil/latanoprost FDC met the criteria for superiority to each active component at all 9 time points (all P < .0001), lowering IOP by an additional 1.8-3.0 mm Hg vs netarsudil and an additional 1.3-2.5 mm Hg vs latanoprost. At month 3, the proportion of patients achieving mean diurnal IOP ≤15 mm Hg was 43.5% for netarsudil/latanoprost FDC, 22.7% for netarsudil, and 24.7% for latanoprost. No treatment-related serious adverse events were reported; treatment-related systemic adverse events were minimal. The most frequent ocular adverse event was conjunctival hyperemia (netarsudil/latanoprost FDC, 53.4%; netarsudil, 41.0%; latanoprost, 14.0%), which led to treatment discontinuation in 7.1% (netarsudil/latanoprost FDC), 4.9% (netarsudil), and 0% (latanoprost) of patients. CONCLUSIONS: Once-daily netarsudil/latanoprost FDC demonstrated IOP reductions that were statistically and clinically superior to netarsudil and latanoprost across all 9 time points through month 3, with acceptable ocular safety.
Authors: Jae-Chiang Wong; Eric J Shiuey; Reza Razeghinejad; Aakriti G Shukla; Natasha N Kolomeyer; Jonathan S Myers; Michael J Pro; Daniel Lee Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-07-29 Impact factor: 3.535
Authors: Kelly A Leary; Kuan-Ting Lin; Juan P Steibel; Christine D Harman; András M Komáromy Journal: Vet Ophthalmol Date: 2019-12-24 Impact factor: 1.644
Authors: Kelly A Leary; Juan P Steibel; Christine D Harman; Amanda L Anderson; András M Komáromy Journal: Vet Ophthalmol Date: 2021-06-04 Impact factor: 1.644
Authors: Haochen Xu; Marwa T Thomas; Dayeong Lee; Matthew T Hirabayashi; Jella A An Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-03-11 Impact factor: 3.535
Authors: Michael P Vincent; Trevor Stack; Amir Vahabikashi; Guorong Li; Kristin M Perkumas; Ruiyi Ren; Haiyan Gong; W Daniel Stamer; Mark Johnson; Evan A Scott Journal: ACS Appl Mater Interfaces Date: 2021-07-07 Impact factor: 10.383